User login
Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.
Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.
Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.
Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.
Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9
Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.
Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.
Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.
Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.
Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9
Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.
Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.
Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.
Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.
Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9